Georgia Esoteric & Molecular Labs, LLC
1120 15th Street BF-207 Augusta, GA 30912 TEL: 706♦721♦5116 FAX: 706♦721♦5117

EGFR by FISH

Test Ordering Code:	2051
CPT Codes:	88368 x 2
Specimen:	Two to three slides of 3-4 micron thick sections of formalin fixed, paraffin embedded breast tissue blocks transported at 20-25 C. Please include one hematoxylin and eosin stained slide and the pathology report or the tissue selection for assay should be performed by a pathologist. Specimens fixed in any other fixative except formalin will not be accepted.
Turnaround Time:	5 - 7 business days
Clinical Significance:	Recent evidence suggests that a combination of clinical data (patient age, tumor location, etc.) and molecular markers may be important in determining prognosis in patients with Glioblastoma Multiforme. Specifically, the determination of "primary" vs. "secondary" glioblastoma may be important in determining prognosis. GEMLab supplements traditional diagnostic methods with analysis of Epidermal Growth Factor Receptor amplification (EGFR) and chromosome 10q deletions (PTEN) as an aid in properly classifying Glioblastomas.
Indications for Testing:	Patients with Astrocytoma, WHO grades III - IV
Methodology:	Fluorescent in situ Hybridization (FISH). Fluorescently labeled DNA probes representing the EGFR gene and a centromeric probe for chromosome #7 are used to detect deletions and numerical abnormalities of the chromosome.
Reporting of Results:	Not Amplified: EGFR: CEP 7<2.0 Amplified: EGFR: CEP 7>2.0
References:	Schmidt MC, Antweiler S, Urban N, et al. Impact of Genotype Morphology on the Prognosis of Glioblastoma. J Neuropathol Exp Neurol 61:321-328, 2002.